Cargando…
FRI158 Efficacy Of Oral Furosemide Test For Primary Aldosteronism Diagnosis
Disclosure: T. Castanheira de Freitas: None. A.W. Maciel: None. G.F. Fagundes: None. J. Petenuci: None. L. Santana: None. A. Guimaraes: None. F. Freitas-Castro: None. V. Srougi: None. F. Tanno: None. J. Chambo: None. M. Pereira: None. F. Coelho: None. L.P. Brito: None. A. Cavalcante: None. B. Pilan:...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554602/ http://dx.doi.org/10.1210/jendso/bvad114.670 |
_version_ | 1785116451331375104 |
---|---|
author | de Freitas, Thaís Castanheira Maciel, Ana Alice W Cardoso Fagundes, Gustavo Freitas Petenuci, Janaina Santana, Lucas Guimaraes, Augusto Freitas-Castro, Felipe Srougi, Victor Tanno, Fabio Chambo, Jose Adelaide Pereira, Maria Coelho, Fernando Pinto Brito, Luciana Cavalcante, Aline Pilan, Bruna Carnevale, Francisco Pio-Abreu, Andrea Bortolotto, Luiz A Claudia Latronico, Ana Villares Fragoso, Maria Candida Barisson Drager, Luciano Bilharinho Mendonca, Berenice Almeida, Madson Q |
author_facet | de Freitas, Thaís Castanheira Maciel, Ana Alice W Cardoso Fagundes, Gustavo Freitas Petenuci, Janaina Santana, Lucas Guimaraes, Augusto Freitas-Castro, Felipe Srougi, Victor Tanno, Fabio Chambo, Jose Adelaide Pereira, Maria Coelho, Fernando Pinto Brito, Luciana Cavalcante, Aline Pilan, Bruna Carnevale, Francisco Pio-Abreu, Andrea Bortolotto, Luiz A Claudia Latronico, Ana Villares Fragoso, Maria Candida Barisson Drager, Luciano Bilharinho Mendonca, Berenice Almeida, Madson Q |
author_sort | de Freitas, Thaís Castanheira |
collection | PubMed |
description | Disclosure: T. Castanheira de Freitas: None. A.W. Maciel: None. G.F. Fagundes: None. J. Petenuci: None. L. Santana: None. A. Guimaraes: None. F. Freitas-Castro: None. V. Srougi: None. F. Tanno: None. J. Chambo: None. M. Pereira: None. F. Coelho: None. L.P. Brito: None. A. Cavalcante: None. B. Pilan: None. F. Carnevale: None. A. Pio-Abreu: None. L. Bortolotto: None. A. Latronico: None. M.C. Fragoso: None. L. Drager: None. B.B. Mendonca: None. M.Q. Almeida: None. Background: Confirmatory tests represent a fundamental step in primary aldosteronism (PA) diagnosis, but they are laborious and often require a hospital environment due to the risks involved. The most common tests are the saline infusion test (SIT), captopril chalenging test (CCT), fludrocortisone supression test (FST) and furosemide upright test (FUT). The sodium overloading tests are the most frequently used tests in clinical practice, but are not tolerated in patients with severe hypertension, hypervolemia and hypokalemia. The use of oral furosemide test as a new confirmatory test to simplify the confirmation of PA diagnosis was not investigated. Methods: We prospectively evaluated the diagnostic performance of oral 80 mg furosemide in 64 PA patients and in 22 with primary hypertension (controls). Direct renin concentration (DRC) was measured before, 2h and 3h after the oral furosemide. In addition, the oral furosemide test was compared with two other confirmatory tests: FUT and SIT or CCT in all PA patients. Results: The cut-off of 7.6 µU/mL for DRC at 2h after oral furosemide had a sensitivity of 92%, a specificity of 82% and an accuracy of 90% for PA diagnosis. The cut-off of 10 µU/mL at 2h had a higher sensitivity of 95.3%, but a lower specificity of 73%. In five out of six controls with low-renin hypertension, which might represent a PA spectrum, renin remained suppressed. Excluding these six controls with low-renin hypertension, the DRC cut-off of 10 µU/mL at 2h after oral furosemide had a sensitivity of 95.3%, a specificity of 93.7% and an accuracy of 95% for PA diagnosis. DRC after 3h of oral furosemide did not improve diagnostic performance. Using the cut-off of 10 µU/mL, the oral furosemide test and the FUT were concordant in 62 out of 64 (97%) PA patients. Only 4 out of 64 PA cases (6.4%) ended the oral furosemide test with potassium <3.5 mEq/L. Hypotension was not evidenced in any PA patient during the test. Conclusion: The oral furosemide test was safe, well-tolerated and represents an effective strategy for PA investigation.Support: Sao Paulo Research Foundation (FAPESP) grant 2019/15873-6 (to M.Q. Almeida) and by the Coordination of Superior Level Staff Improvement (CAPES) fellowship (to TCF). Presentation: Friday, June 16, 2023 |
format | Online Article Text |
id | pubmed-10554602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105546022023-10-06 FRI158 Efficacy Of Oral Furosemide Test For Primary Aldosteronism Diagnosis de Freitas, Thaís Castanheira Maciel, Ana Alice W Cardoso Fagundes, Gustavo Freitas Petenuci, Janaina Santana, Lucas Guimaraes, Augusto Freitas-Castro, Felipe Srougi, Victor Tanno, Fabio Chambo, Jose Adelaide Pereira, Maria Coelho, Fernando Pinto Brito, Luciana Cavalcante, Aline Pilan, Bruna Carnevale, Francisco Pio-Abreu, Andrea Bortolotto, Luiz A Claudia Latronico, Ana Villares Fragoso, Maria Candida Barisson Drager, Luciano Bilharinho Mendonca, Berenice Almeida, Madson Q J Endocr Soc Cardiovascular Endocrinology Disclosure: T. Castanheira de Freitas: None. A.W. Maciel: None. G.F. Fagundes: None. J. Petenuci: None. L. Santana: None. A. Guimaraes: None. F. Freitas-Castro: None. V. Srougi: None. F. Tanno: None. J. Chambo: None. M. Pereira: None. F. Coelho: None. L.P. Brito: None. A. Cavalcante: None. B. Pilan: None. F. Carnevale: None. A. Pio-Abreu: None. L. Bortolotto: None. A. Latronico: None. M.C. Fragoso: None. L. Drager: None. B.B. Mendonca: None. M.Q. Almeida: None. Background: Confirmatory tests represent a fundamental step in primary aldosteronism (PA) diagnosis, but they are laborious and often require a hospital environment due to the risks involved. The most common tests are the saline infusion test (SIT), captopril chalenging test (CCT), fludrocortisone supression test (FST) and furosemide upright test (FUT). The sodium overloading tests are the most frequently used tests in clinical practice, but are not tolerated in patients with severe hypertension, hypervolemia and hypokalemia. The use of oral furosemide test as a new confirmatory test to simplify the confirmation of PA diagnosis was not investigated. Methods: We prospectively evaluated the diagnostic performance of oral 80 mg furosemide in 64 PA patients and in 22 with primary hypertension (controls). Direct renin concentration (DRC) was measured before, 2h and 3h after the oral furosemide. In addition, the oral furosemide test was compared with two other confirmatory tests: FUT and SIT or CCT in all PA patients. Results: The cut-off of 7.6 µU/mL for DRC at 2h after oral furosemide had a sensitivity of 92%, a specificity of 82% and an accuracy of 90% for PA diagnosis. The cut-off of 10 µU/mL at 2h had a higher sensitivity of 95.3%, but a lower specificity of 73%. In five out of six controls with low-renin hypertension, which might represent a PA spectrum, renin remained suppressed. Excluding these six controls with low-renin hypertension, the DRC cut-off of 10 µU/mL at 2h after oral furosemide had a sensitivity of 95.3%, a specificity of 93.7% and an accuracy of 95% for PA diagnosis. DRC after 3h of oral furosemide did not improve diagnostic performance. Using the cut-off of 10 µU/mL, the oral furosemide test and the FUT were concordant in 62 out of 64 (97%) PA patients. Only 4 out of 64 PA cases (6.4%) ended the oral furosemide test with potassium <3.5 mEq/L. Hypotension was not evidenced in any PA patient during the test. Conclusion: The oral furosemide test was safe, well-tolerated and represents an effective strategy for PA investigation.Support: Sao Paulo Research Foundation (FAPESP) grant 2019/15873-6 (to M.Q. Almeida) and by the Coordination of Superior Level Staff Improvement (CAPES) fellowship (to TCF). Presentation: Friday, June 16, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554602/ http://dx.doi.org/10.1210/jendso/bvad114.670 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Cardiovascular Endocrinology de Freitas, Thaís Castanheira Maciel, Ana Alice W Cardoso Fagundes, Gustavo Freitas Petenuci, Janaina Santana, Lucas Guimaraes, Augusto Freitas-Castro, Felipe Srougi, Victor Tanno, Fabio Chambo, Jose Adelaide Pereira, Maria Coelho, Fernando Pinto Brito, Luciana Cavalcante, Aline Pilan, Bruna Carnevale, Francisco Pio-Abreu, Andrea Bortolotto, Luiz A Claudia Latronico, Ana Villares Fragoso, Maria Candida Barisson Drager, Luciano Bilharinho Mendonca, Berenice Almeida, Madson Q FRI158 Efficacy Of Oral Furosemide Test For Primary Aldosteronism Diagnosis |
title | FRI158 Efficacy Of Oral Furosemide Test For Primary Aldosteronism Diagnosis |
title_full | FRI158 Efficacy Of Oral Furosemide Test For Primary Aldosteronism Diagnosis |
title_fullStr | FRI158 Efficacy Of Oral Furosemide Test For Primary Aldosteronism Diagnosis |
title_full_unstemmed | FRI158 Efficacy Of Oral Furosemide Test For Primary Aldosteronism Diagnosis |
title_short | FRI158 Efficacy Of Oral Furosemide Test For Primary Aldosteronism Diagnosis |
title_sort | fri158 efficacy of oral furosemide test for primary aldosteronism diagnosis |
topic | Cardiovascular Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554602/ http://dx.doi.org/10.1210/jendso/bvad114.670 |
work_keys_str_mv | AT defreitasthaiscastanheira fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT macielanaalicew fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT cardosofagundesgustavofreitas fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT petenucijanaina fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT santanalucas fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT guimaraesaugusto fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT freitascastrofelipe fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT srougivictor fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT tannofabio fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT chambojose fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT adelaidepereiramaria fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT coelhofernando fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT pintobritoluciana fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT cavalcantealine fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT pilanbruna fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT carnevalefrancisco fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT pioabreuandrea fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT bortolottoluiza fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT claudialatronicoana fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT villaresfragosomariacandidabarisson fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT dragerluciano fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT bilharinhomendoncaberenice fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis AT almeidamadsonq fri158efficacyoforalfurosemidetestforprimaryaldosteronismdiagnosis |